Opinion & analysis

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

Robert Temple, the FDA’s voice of institutional memory, believes drug regulation has quietly entered a third era: the “Age of Individualization.” Unlike the prior eras of safety and efficacy, there is no milestone legislation to set the ground rules. But, Temple stressed, there have been significant changes in areas like the assessment of drug-drug interactions, metabolic response to therapeutics, and in the FDA’s willingness for sub-population analyses. Is there a change in the air that will result in further change in drug development as it relates to the Age of the Individual?

New Age Thinking: US FDA’s Temple Sees Third Era Of Drug Development

US FDA’s Rush Following Novartis’ Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation

FDA’s Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident

Contamination In Common OTC Antacid Adds To FDA’s API Impurity Concerns

US Zantac Sales And Distribution Continue As Sanofi Tests For NDMA

Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’

Sanofi Offloads Two German OTC Brands, New CEO Prepares To Make Mark

Sunscreen Test Lab Used Fewer Subjects Than Reported, US Prosecutors Allege

L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’

Reckitt Invests In AI Symptom Checker To ‘Unlock Self-Care’

CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes

Orphan Drug Pricing And Reimbursement: Challenges To Patient Access

IXICO Targets Go-To Status In Neuro Data Analytics Space

FDA Announces More Actions On Drug-Coated Devices